Cargando…

Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma

BACKGROUND: Infantile hemangiomas (IHs) are the most common benign vascular tumor of infancy. They occur more frequently in female infants. The cause of hemangioma is currently unknown; however, current studies suggested the importance of estrogen (E2) signaling in hemangioma proliferation. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ling, Wu, Hai Wei, Yuan, Weien, Zheng, Jia Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511019/
https://www.ncbi.nlm.nih.gov/pubmed/28744158
http://dx.doi.org/10.2147/CMAR.S138687
_version_ 1783250264322473984
author Zhang, Ling
Wu, Hai Wei
Yuan, Weien
Zheng, Jia Wei
author_facet Zhang, Ling
Wu, Hai Wei
Yuan, Weien
Zheng, Jia Wei
author_sort Zhang, Ling
collection PubMed
description BACKGROUND: Infantile hemangiomas (IHs) are the most common benign vascular tumor of infancy. They occur more frequently in female infants. The cause of hemangioma is currently unknown; however, current studies suggested the importance of estrogen (E2) signaling in hemangioma proliferation. METHODS: Hemangioma-derived stem cells (HemSCs) were cultured with estrogen for 48–72 h; the cell viability and proliferation were evaluated with the messenger RNA (mRNA) and protein expression levels of fibroblast growth factor 2 (FGF2), vascular endothelial growth factor-A (VEGF-A) and estrogen receptor-α (ER-α), by application of several in vitro assays, such as methyl thiazolyl tetrazolium (MTT), reverse transcriptase–polymerase chain reaction (RT-PCR), real-time PCR, enzyme-linked immunosorbent assay (ELISA) and Western blotting. Also, the cell population’s response to external estrogen was investigated by in vivo experiments. HemSCs and human umbilical vein endothelial cells (HUVECs) were mixed and injected subcutaneously into 20 flank of BALB/c-nu mice, which were randomly divided into 5 groups based on different E2 treatment doses (0, 0.01, 0.1 and 1 mg, respectively), 0.1 mg dimethyl sulfoxide (DMSO) as control. Each group of mice were treated intramuscularly every week, then 2 and 4 weeks later, the subcutaneous implants were harvested and evaluated the tumor tissues with microvessel density (MVD) assay and immunohistochemistry. RESULTS: The study demonstrated that application of E2 increased the expression of FGF2, VEGF-A, and ER-α in HemSCs with the optimal concentration from 10(−9) to 10(−5) M. Two-week treatment of E2 promoted expression of VEGF-A and FGF2 in HemSCs culture. Morphological, histological and immunohistological improvements were observed in vivo using murine IH model in which HemSCs and HUVECs were implanted into BALB/c-nu mice that were post-injected with E2. In the grafts, mean MVD was markedly increased. CONCLUSION: The results suggested that E2 promotes angiogenesis via combination with ER-α to up-regulate the expression of VEGF-A in HemSCs, promoting proliferation of IHs. These findings provide critical insight into the potential mechanisms of E2 action on IHs.
format Online
Article
Text
id pubmed-5511019
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55110192017-07-25 Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma Zhang, Ling Wu, Hai Wei Yuan, Weien Zheng, Jia Wei Cancer Manag Res Original Research BACKGROUND: Infantile hemangiomas (IHs) are the most common benign vascular tumor of infancy. They occur more frequently in female infants. The cause of hemangioma is currently unknown; however, current studies suggested the importance of estrogen (E2) signaling in hemangioma proliferation. METHODS: Hemangioma-derived stem cells (HemSCs) were cultured with estrogen for 48–72 h; the cell viability and proliferation were evaluated with the messenger RNA (mRNA) and protein expression levels of fibroblast growth factor 2 (FGF2), vascular endothelial growth factor-A (VEGF-A) and estrogen receptor-α (ER-α), by application of several in vitro assays, such as methyl thiazolyl tetrazolium (MTT), reverse transcriptase–polymerase chain reaction (RT-PCR), real-time PCR, enzyme-linked immunosorbent assay (ELISA) and Western blotting. Also, the cell population’s response to external estrogen was investigated by in vivo experiments. HemSCs and human umbilical vein endothelial cells (HUVECs) were mixed and injected subcutaneously into 20 flank of BALB/c-nu mice, which were randomly divided into 5 groups based on different E2 treatment doses (0, 0.01, 0.1 and 1 mg, respectively), 0.1 mg dimethyl sulfoxide (DMSO) as control. Each group of mice were treated intramuscularly every week, then 2 and 4 weeks later, the subcutaneous implants were harvested and evaluated the tumor tissues with microvessel density (MVD) assay and immunohistochemistry. RESULTS: The study demonstrated that application of E2 increased the expression of FGF2, VEGF-A, and ER-α in HemSCs with the optimal concentration from 10(−9) to 10(−5) M. Two-week treatment of E2 promoted expression of VEGF-A and FGF2 in HemSCs culture. Morphological, histological and immunohistological improvements were observed in vivo using murine IH model in which HemSCs and HUVECs were implanted into BALB/c-nu mice that were post-injected with E2. In the grafts, mean MVD was markedly increased. CONCLUSION: The results suggested that E2 promotes angiogenesis via combination with ER-α to up-regulate the expression of VEGF-A in HemSCs, promoting proliferation of IHs. These findings provide critical insight into the potential mechanisms of E2 action on IHs. Dove Medical Press 2017-07-07 /pmc/articles/PMC5511019/ /pubmed/28744158 http://dx.doi.org/10.2147/CMAR.S138687 Text en © 2017 Zhang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Zhang, Ling
Wu, Hai Wei
Yuan, Weien
Zheng, Jia Wei
Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma
title Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma
title_full Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma
title_fullStr Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma
title_full_unstemmed Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma
title_short Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma
title_sort estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511019/
https://www.ncbi.nlm.nih.gov/pubmed/28744158
http://dx.doi.org/10.2147/CMAR.S138687
work_keys_str_mv AT zhangling estrogenmediatedhemangiomaderivedstemcellsthroughestrogenreceptoraforinfantilehemangioma
AT wuhaiwei estrogenmediatedhemangiomaderivedstemcellsthroughestrogenreceptoraforinfantilehemangioma
AT yuanweien estrogenmediatedhemangiomaderivedstemcellsthroughestrogenreceptoraforinfantilehemangioma
AT zhengjiawei estrogenmediatedhemangiomaderivedstemcellsthroughestrogenreceptoraforinfantilehemangioma